Establish Your Innovation Hub at RESI JPM 2027

August 4, 2026 ~ Next Phase Admin ~ Leave a comment

By Max Braht, VP of Business Development, LSN

Every January, JPM Healthcare Week transforms San Francisco into the global center of the life science industry, bringing together investors, pharmaceutical executives, biotech leaders, and innovators from around the world. For organizations looking to showcase their regional ecosystem, portfolio companies, or innovation network, RESI JPM 2027 offers a unique opportunity to establish a visible and strategic presence during one of the industry’s most influential weeks.

Located within the San Francisco Marriott Marquis, RESI JPM is the premier partnering conference dedicated to early-stage life science companies. The event connects startups with active investors, strategic partners, and business development professionals through curated partnering meetings, educational programming, and networking opportunities.

Life Science Nation invites regional organizations, innovation hubs, accelerators, and industry partners to create their own branded Innovation Hub alongside RESI JPM. These flexible hosting opportunities allow organizations to provide a central gathering place for their ecosystem while taking advantage of the high concentration of attendees already participating in RESI and JPM Healthcare Week.

RESI JPM 2027 Venue: Salons 9–15 (Yerba Buena Ballroom, Lower B2 Level) with total space exceeding 17,000 sq ft.

Organizations can kick off the week with a private networking reception on Sunday, welcoming investors, founders, corporate partners, and key stakeholders before the week’s meetings begin. During RESI JPM on Monday and Tuesday, dedicated salon spaces adjacent to the conference offer an ideal location for hosting meetings, showcasing portfolio companies, conducting presentations, and serving as a home base for delegates throughout the event.

Tech/Innovation hubs also benefit from prominent branding within the RESI environment and the opportunity for their startup cohorts to engage directly in RESI’s partnering platform, creating additional exposure and meeting opportunities with investors and strategic partners.

Whether representing a regional life science cluster, government agency, incubator, accelerator, or investment organization, establishing an Innovation Hub at RESI JPM positions your organization at the center of the world’s largest life science partnering week while providing lasting value for your innovation ecosystem.

To learn more about creating an Innovation Hub at RESI JPM 2027, contact Life Science Nation at salescore@lifesciencenation.com.

Meet the First Believers: The Investors Behind Tomorrow’s Breakthrough Companies

August 4, 2026 ~ Next Phase Admin ~ Leave a comment

By Momo Yamamoto, Senior Investor Research Analyst, LSN

Every successful life science company has a defining moment in its fundraising journey. Long before a major venture capital round or strategic partnership, there is often an investor willing to take the very first leap of faith.

At 9:00 AM on Wednesday, September 23, Day 2 of RESI Boston 2026 begins with one of the conference’s most valuable discussions for early-stage founders: The First Believers: The Investors Behind Tomorrow’s Breakthrough Companies.

Securing that first investment is about much more than capital. Early investors provide critical validation, open doors to strategic relationships, and help companies build the momentum needed to attract future financing. Understanding how these investors think can give entrepreneurs a significant advantage as they prepare for fundraising.

This panel brings together accomplished investors and innovation leaders who regularly evaluate breakthrough technologies at their earliest stages:

Renaud Jacquemart Omnium Global (Moderator)	Sam Gussman-Toh ARPA-H	William Hsu, PhD NuFund Venture Group
Rohit Jain HBS Alumni Angels of Northern California	Dushyant Pathak Autobahn Labs

These panelists represent a diverse range of perspectives across venture creation, angel investing, government-supported innovation, and early-stage venture capital. Collectively, they helped identify and support companies long before they became widely recognized.

During the discussion, attendees will gain insight into what separates promising startups from investable opportunities. The panel will explore the characteristics investors look for in founding teams, the technical and commercial milestones that inspire confidence, and the common mistakes entrepreneurs make when approaching investors during the earliest stages of fundraising.

The conversation will also address how startups can build credibility before institutional financing, demonstrate meaningful progress with limited resources, and develop fundraising strategies that position them for long-term success.

For founders preparing to raise their first outside capital, this session offers a rare opportunity to hear directly from the investors who are often the first to believe in transformative science and technology.

Whether you are refining your investment story, preparing for investor meetings, or mapping out your fundraising roadmap, The First Believers panel will provide practical insights that can help shape your next steps.

Don’t miss this opportunity to kick off Day 2 of RESI Boston with an inside look at how early-stage investors identify the breakthrough companies of tomorrow.

Build an Investor-Ready Company with Life Science Nation’s Education Program

August 4, 2026August 4, 2026 ~ Next Phase Admin ~ Leave a comment

By Karen Deyo, VP of Product, Israel BD, LSN

Raising capital is more than having innovative science. Early-stage life science companies also need a compelling story, a clear fundraising strategy, and the ability to engage the right investors. Life Science Nation’s (LSN) Education Program helps founders build those skills, preparing them for a successful fundraising campaign that typically spans 9 to 18 months.

Designed for biotechnology, medical device, diagnostics, digital health, and life science tool companies, the program gives entrepreneurs practical guidance while helping accelerators, incubators, universities, and regional innovation organizations better prepare their portfolio companies for investor engagement.

Two Programs, One Goal
Organizations can choose the level of support that best fits their companies’ needs.

Preparing and Executing a RESI Event includes:

Three virtual education sessions
In-person Pitch Practice and Shark Tank before RESI

Preparing and Executing a Global Roadshow includes:

Twelve virtual education sessions
A dedicated LSN mentor with coaching between classes
In-person Pitch Practice and Shark Tank

Throughout the curriculum, founders learn how investors evaluate opportunities, refine their branding and messaging, align fundraising goals with company milestones, and develop a systematic approach to investor outreach. Participants also learn how to navigate the RESI Partnering Platform, identify the right investors, execute productive meetings, and build an effective follow-up strategy after the conference.

The program concludes with an in-person Pitch Practice and Shark Tank held before RESI, giving companies the opportunity to present their technology, receive live feedback, and strengthen their investor presentations before meeting with active investors.

Putting Preparation into Practice

The Education Program is designed to prepare companies for the Redefining Early Stage Investments (RESI) Conference Series, where startups connect with active investors, pharmaceutical companies, strategic partners, and service providers from across the global life science ecosystem.

Companies can further increase their visibility by participating in the Innovator’s Pitch Challenge (IPC). Each company delivers a six-minute presentation followed by seven minutes of investor Q&A, while also showcasing its technology in the RESI Exhibition Hall. IPC participants receive additional exposure through the LSN Newsletter and RESI Program Guide, with audience voting determining the competition winners.

Together, the Education Program, RESI Conference, and Innovator’s Pitch Challenge provide founders with a complete framework for fundraising success—from developing an investor-ready message to building meaningful relationships that can help move their companies forward.

Interested in bringing the Life Science Nation Education Program to your portfolio companies? Visit www.lifesciencenation.com and www.resiconference.com to learn more.

Hot Investor Mandate: Early-Stage VC Invests Up to $15M Over Company Lifecycle, Seeking Medical Devices, Diagnostics, and R&D and Life Science Tools

July 28, 2026 ~ Next Phase Admin ~ Leave a comment

The firm is an early-stage venture capital firm that primarily invests at the Seed and Series A stages, often serving as the first institutional investor in its portfolio companies. Initial investments typically range from approximately $500K to $7M, with the capacity to invest $15M or more over the life of a company. The firm invests globally but maintains a strong focus on opportunities emerging from major innovation hubs in the United States. The firm follows a thesis-driven investment strategy centered on building category-defining companies addressing large, underserved markets.

Within healthcare, the firm invests in medical technology, medical devices, diagnostics, genomics-enabled diagnostics, bioinformatics platforms, laboratory services, and other data-driven healthcare businesses. The firm seeks disruptive technologies capable of transforming large clinical markets, with particular interest in opportunities addressing diabetes, cardiovascular disease, hypertension, obesity, and other significant unmet healthcare needs. The firm emphasizes scalable business models, differentiated innovation, and the potential to create or redefine large markets.

From a company and management team perspective, the firm frequently serves as the lead or co-lead investor and takes an active board role. The firm works closely with portfolio companies on strategy, executive recruitment, product development, commercialization, and fundraising. While experienced leadership teams are valued, the firm is also willing to back first-time founders who demonstrate exceptional vision, technical expertise, and the ability to execute against large market opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: VC Investor Focuses on Investing and Supporting Trials of Early Clinical Stage Therapeutics and Medical Technologies

July 28, 2026 ~ Next Phase Admin ~ Leave a comment

The firm is an international venture capital firm focused on investing in clinical-stage healthcare companies. The firm invests primarily in companies advancing therapeutic programs while also considering opportunities in diagnostics, medical devices, and digital health. The firm generally targets companies conducting Phase I or Phase II clinical trials or equivalent stages of development and invests across major healthcare markets.

The firm’s primary focus is therapeutics, although it remains open to diagnostics, medical devices, and digital health opportunities. The firm is generally indication-agnostic but has particular interest in diabetes, pulmonology, ophthalmology, oncology, and other areas with significant unmet medical need. The firm prioritizes companies with meaningful clinical validation and strong translational potential.

From a company and management team perspective, the firm typically participates as a co-investor and generally prefers opportunities that already have a lead investor in place. The firm does not typically require board representation and does not have specific management team requirements, allowing it to work with a broad range of experienced and emerging leadership teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: Europe-Based VC Invests Up to €15M in Digital Health, MedTech, and Healthcare Technology Companies

July 28, 2026 ~ Next Phase Admin ~ Leave a comment

The firm is a European venture capital firm focused on early-stage technology and healthcare investments. The firm primarily invests at the Seed and Series A stages, with selective participation in Series B financings and significant follow-on capacity. Initial investments typically range from approximately €500K to €3M, with total commitments of up to €10M–15M per portfolio company. The firm has established a dedicated healthcare investment platform supported by strategic partners across the healthcare ecosystem and primarily invests in companies across Europe.

The firm focuses primarily on digital health, including health data platforms, diagnostics, care delivery technologies, clinical workflow solutions, and other enabling healthcare technologies. The firm also selectively invests in medical technology companies, particularly those incorporating connected care, artificial intelligence, or digital components. The firm seeks businesses with differentiated technologies capable of improving clinical outcomes or healthcare system efficiency.

From a company and management team perspective, the firm is an active investor that frequently serves as lead investor and consistently takes a board seat. The firm works closely with portfolio companies on corporate strategy, financing, talent recruitment, business development, and strategic partnerships, providing hands-on operational support throughout the company’s growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: Global CVC Strategically Invests Up to $5M in Digital Health Companies Across All Stages

July 28, 2026 ~ Next Phase Admin ~ Leave a comment

A corporate venture capital arm of a global pharmaceutical company invests in innovative digital health companies worldwide. Established in 2015, the firm supports companies from Seed through later-stage venture financings and can invest up to approximately $5M per financing round. The firm seeks strategic investments that complement its parent company’s long-term healthcare priorities while helping portfolio companies accelerate product development and commercial adoption.

The firm focuses exclusively on digital health, with particular interest in prevention and medication adherence technologies, digital therapeutics, digital medical devices, and big data analytics platforms. Key areas of interest include chronic diseases such as diabetes, obesity, and cardiovascular disease, as well as respiratory diseases, oncology, consumer health, and mental health. The firm seeks innovative technologies that improve patient outcomes through connected care, data-driven insights, and digital healthcare solutions.

From a company and management team perspective, the firm prefers experienced leadership teams with demonstrated expertise in their respective markets and well-developed business plans. The firm partners with companies globally and seeks management teams capable of successfully commercializing innovative digital health technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.